Pharmacoeconomic evaluation of pomalidomide (imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide and bortezomib
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.